公开(公告)号：WO2022173931A1

公开(公告)日：2022-08-18

申请号：PCT/US2022/015950

申请日：2022-02-10

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： MILLER, Elizabeth ,  LOWY, Israel ,  THURSTON, Gavin ,  MERAD, Miriam ,  MARRON, Thomas ,  SCHWARTZ, Myron

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).